Skip to main content

Anti-CD19/CD20/CD22 CAR T-Cells

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

  • RegistryNCT05418088
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Acute Lymphoblastic Leukemia
  • SponsorSumithira Vasu
How Anti-CD19/CD20/CD22 CAR T-Cells worksNCT054180881 min

What the film says

Read the transcript

CAR T cells aimed at CD19 have rescued many people with relapsed B-cell leukemias and lymphomas. But the cancer adapts: drop CD19 from the surface, and the cells lose their target.

The idea: give the cancer three targets to lose instead of one.

At Ohio State and Nationwide Children's, a patient's T cells receive a single receptor that recognizes CD19, CD20, and CD22, three proteins found on B-cell cancers. After a short course of chemotherapy makes room, the cells go in as one infusion. Cohorts separate lower-burden disease from bulkier, faster leukemia and lymphoma, and the study includes children from age two.

An early safety and dose-finding trial. Sumithira Vasu leads it, with Margaret Lamb for pediatric patients. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05418088

    Tri-specific CD19/CD20/CD22 receptor; Cy day −6, Flu days −5 to −3; single infusion day 0; Cohort A (lesions ≤5 cm, indolent, CLL, B-PLL) vs Cohort B (blast crisis, ALL, Richter's, bulky NHL); Ages 2+; Sumithira Vasu (OSU), Margaret Lamb (Nationwide Children's)

The drug

What is being tested.

PRIMARY OBJECTIVE: I. To determine the safety of the treatment of relapsed/refractory non-Hodgkin lymphoma, relapsed/refractory chronic lymphocytic leukemia, refractory B-prolymphocytic leukemia and relapsed/refractory acute lymphoblastic leukemia with chimeric antigen receptor T cells targeting CD19/20/22 and to find the recommended phase II dose for this cellular therapy. SECONDARY OBJECTIVES: I.

To describe the safety profile of the infusion of CAR-T cells targeting CD19/20/22 in relapsed/refractory Non-Hodgkin lymphoma, relapsed/refractory chronic lymphocytic leukemia, refractory B-prolymphocytic leukemia and in relapsed/refractory acute lymphoblastic leukemia. II. To describe the toxicities related to infusion of CAR-T cells targeting CD19/20/22. III.

CAR T-cells are made by taking a patient's own T-cells and genetically modifying them with a virus so that they are recognized by a group of proteins called CD19/CD20/CD22 which are found on the surface of cancer cells. Anti-CD19/CD20/CD22 CAR T-cells can recognize CD19/CD20/CD22, bind to the cancer cells and kill them. Giving combination chemotherapy helps prepare the body before CAR T-cell therapy.

The study

How the trial runs.

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine in treating patients with lymphoid cancers (malignancies) that have come back (recurrent) or do not respond to treatment (refractory).

Lymphoid malignancies eligible for this trial are: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-prolymphocytic leukemia (B-PLL). T-cells (a type of white blood cell) form part of the body's immune system. CAR-T is a type of cell therapy that is used with gene-based therapies.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Adult subjects with relapsed or refractory non-Hodgkin lymphoma with lesions =< 5 cm, indolent lymphomas, chronic lymphocytic leukemia without Richter's transformation, or B-prolymphocytic leukemia (Cohort A)
  • OR adult subjects with lymphoid blast crisis, acute lymphoblastic leukemia, chronic lymphocytic leukemia with Richter's transformation, non-Hodgkin lymphoma with lesions > 5 cm and/or lymphoblastic lymphoma, or non-Hodgkin lymphoma with circulating lymphoma cells, B-Prolymphocytic leukemia with lesions > 5 cm (not including splenomegaly (Cohort B).
  • OR Pediatric subjects with Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
  • Subjects must have been treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve complete remission with the last regimen. B-PLL is defined as having greater than 55% prolymphocytes in the peripheral blood
  • Subjects with relapsed/refractory CLL after at least 2 prior lines of appropriate therapy and must have previously received an approved BTK inhibitor and venetoclax
  • Subjects with refractory high-grade B-cell lymphoma who relapse within 12 months of autologous stem cell transplant

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.